---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-24-000033"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:43:15.836041+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics reports Q3 net loss $16.7M; WTX-330 partial response in melanoma

## Summary
- Net loss $16.7M for Q3 2024 vs $8.3M in Q3 2023; cash $122.8M, runway through Q2 2026.
- WTX-124 monotherapy expansion arms enrolling; initial efficacy data expected H1 2025.
- WTX-330 interim data at SITC: 25 patients, 22-fold higher exposure vs rhIL-12, confirmed partial response in melanoma.
- New preclinical candidate WTX-921 (IL-10) for inflammatory diseases introduced.
- Two WTX-124 patients with confirmed partial responses; one CSCC patient in complete remission >12 months.

## SEC filing metadata
- accession: 0001785530-24-000033
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000033/0001785530-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553024000033/howl-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-24-000033
- JSON: https://secwatch.observer/filing/0001785530-24-000033.json
- Plain text: https://secwatch.observer/filing/0001785530-24-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.